Biotron Limited is an Australia-based biotechnology company. The Company is engaged in the funding and management of intermediate, and applied technology research and development projects. It is in development and commercialization of small molecule antiviral therapeutics targeting Hepatitis C virus (HCV) and human immunodeficiency virus (HIV)-1. Biotron has a pipeline of clinical programs developing antiviral drugs. Biotron's lead drug, BIT225, is a viroporin inhibitor in clinical development for treatment of HCV and HIV, as well as the hard to treat HIV/HCV co-infected population. It has completed Phase Ib/IIa HIV trial and demonstrated that BIT225 targets HIV replication in monocyte cells in treated patients, reducing virus levels in these cells. Biotron has early-stage programs addressing other viral diseases, including dengue virus. It also has a research and development program for next generation viroporin inhibitors for its HIV/HCV programs.